Sensitization of pancreatic cancer cells to radiation by cerium oxide nanoparticle-induced ROS production
- PMID: 23178284
- PMCID: PMC3606274
- DOI: 10.1016/j.nano.2012.10.010
Sensitization of pancreatic cancer cells to radiation by cerium oxide nanoparticle-induced ROS production
Abstract
Side effect of radiation therapy (RT) remains the most challenging issue for pancreatic cancer treatment. In this report we determined whether and how cerium oxide nanoparticles (CONPs) sensitize pancreatic cancer cells to RT. CONP pretreatment enhanced radiation-induced reactive oxygen species (ROS) production preferentially in acidic cell-free solutions as well as acidic human pancreatic cancer cells. In acidic environments, CONPs favor the scavenging of superoxide radical over the hydroxyl peroxide resulting in accumulation of the latter whereas in neutral pH CONPs scavenge both. CONP treatment prior to RT markedly potentiated the cancer cell apoptosis both in culture and in tumors and the inhibition of the pancreatic tumor growth without harming the normal tissues or host mice. Taken together, these results identify CONPs as a potentially novel RT-sensitizer as well as protectant for improving pancreatic cancer treatment.
From the clinical editor: Pancreatic tumors remain some of the most notoriously treatment-unresponsive malignancies. Cerium oxide nanoparticles may be capable of sensitizing such cells to radiotherapy, as demonstrated in this study.
Copyright © 2013 Elsevier Inc. All rights reserved.
Conflict of interest statement
Figures
Similar articles
-
Cerium Oxide Nanoparticles Sensitize Pancreatic Cancer to Radiation Therapy through Oxidative Activation of the JNK Apoptotic Pathway.Cancers (Basel). 2018 Sep 1;10(9):303. doi: 10.3390/cancers10090303. Cancers (Basel). 2018. PMID: 30200491 Free PMC article.
-
Titanium peroxide nanoparticles enhanced cytotoxic effects of X-ray irradiation against pancreatic cancer model through reactive oxygen species generation in vitro and in vivo.Radiat Oncol. 2016 Jul 7;11(1):91. doi: 10.1186/s13014-016-0666-y. Radiat Oncol. 2016. PMID: 27386977 Free PMC article.
-
Endocytosis of cerium oxide nanoparticles and modulation of reactive oxygen species in human ovarian and colon cancer cells.Acta Biomater. 2017 Mar 1;50:127-141. doi: 10.1016/j.actbio.2016.12.010. Epub 2016 Dec 8. Acta Biomater. 2017. PMID: 27940194
-
Cerium oxide nanoparticles in cancer.Onco Targets Ther. 2014 May 27;7:835-40. doi: 10.2147/OTT.S62057. eCollection 2014. Onco Targets Ther. 2014. PMID: 24920925 Free PMC article. Review.
-
Different approaches to synthesising cerium oxide nanoparticles and their corresponding physical characteristics, and ROS scavenging and anti-inflammatory capabilities.J Mater Chem B. 2021 Sep 22;9(36):7291-7301. doi: 10.1039/d1tb01091c. J Mater Chem B. 2021. PMID: 34355717 Review.
Cited by
-
Cerium oxide nanoparticles: Chemical properties, biological effects and potential therapeutic opportunities (Review).Biomed Rep. 2024 Jan 29;20(3):48. doi: 10.3892/br.2024.1736. eCollection 2024 Mar. Biomed Rep. 2024. PMID: 38357238 Free PMC article. Review.
-
Hybrid Polyelectrolyte Capsules Loaded with Gadolinium-Doped Cerium Oxide Nanoparticles as a Biocompatible MRI Agent for Theranostic Applications.Polymers (Basel). 2023 Sep 21;15(18):3840. doi: 10.3390/polym15183840. Polymers (Basel). 2023. PMID: 37765694 Free PMC article.
-
Nanoceria as Safe Contrast Agents for X-ray CT Imaging.Nanomaterials (Basel). 2023 Jul 29;13(15):2208. doi: 10.3390/nano13152208. Nanomaterials (Basel). 2023. PMID: 37570527 Free PMC article.
-
Current advances in nanoformulations of therapeutic agents targeting tumor microenvironment to overcome drug resistance.Cancer Metastasis Rev. 2023 Sep;42(3):959-1020. doi: 10.1007/s10555-023-10119-w. Epub 2023 Jul 28. Cancer Metastasis Rev. 2023. PMID: 37505336 Review.
-
Nanoparticle-based radiosensitization strategies for improving radiation therapy.Front Pharmacol. 2023 Feb 16;14:1145551. doi: 10.3389/fphar.2023.1145551. eCollection 2023. Front Pharmacol. 2023. PMID: 36873996 Free PMC article. Review.
References
-
- Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist. 2007;12:738–747. - PubMed
-
- Stolarska M, Mlynarski W, Zalewska-Szewczyk B, Bodalski J. Cytoprotective effect of amifostine in the treatment of childhood neoplastic diseases--a clinical study including the pharmacoeconomic analysis. Pharmacol Rep. 2006;58:30–34. - PubMed
-
- Krug LM, Curley T, Schwartz L, Richardson S, Marks P, Chiao J, Kelly WK. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer. 2006;7:257–261. - PubMed
-
- Huang P, Yang DP, Zhang C, Lin J, He M, Bao L, Cui D. Protein-directed one-pot synthesis of Ag microspheres with good biocompatibility and enhancement of radiation effects on gastric cancer cells. Nanoscale. 2011;3:3623–3626. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
